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Abstract
Background: GATA3 is pivotal for the development of T lymphocytes. While its effects in later stages of T cell
differentiation are well recognized, the role of GATA3 in the generation of early T cell precursors (ETP) has only
recently been explored. As aberrant GATA3 mRNA expression has been linked to cancerogenesis, we investigated
the role of GATA3 in early T cell precursor acute lymphoblastic leukemia (ETP-ALL).
Methods: We analyzed GATA3 mRNA expression by RT-PCR (n = 182) in adult patients with T-ALL. Of these, we
identified 70 of 182 patients with ETP-ALL by immunophenotyping. DNA methylation was assessed genome wide
(Illumina Infinium® HumanMethylation450 BeadChip platform) in 12 patients and GATA3-specifically by pyrosequencing
in 70 patients with ETP-ALL. The mutational landscape of ETP-ALL with respect to GATA3 expression was investigated in
18 patients and validated by Sanger sequencing in 65 patients with ETP-ALL. Gene expression profiles (Affymetrix
Human genome U133 Plus 2.0) of an independent cohort of adult T-ALL (n = 83) were used to identify ETP-ALL
and investigate GATA3low and GATA3high expressing T-ALL patients. In addition, the ETP-ALL cell line PER-117 was
investigated for cytotoxicity, apoptosis, GATA3 mRNA expression, DNA methylation, and global gene expression
before and after treatment with decitabine.
Results: In our cohort of 70 ETP-ALL patients, 33 % (23/70) lacked GATA3 expression and were thus defined as
GATA3low. DNA methylation analysis revealed a high degree of GATA3 CpG island methylation in GATA3low
compared with GATA3high ETP-ALL patients (mean 46 vs. 21 %, p < 0.0001). Genome-wide expression profiling of
GATA3low ETP-ALL exhibited enrichment of myeloid/lymphoid progenitor (MLP) and granulocyte/monocyte
progenitor (GMP) genes, while T cell-specific signatures were downregulated compared to GATA3high ETP-ALL.
Among others, FLT3 expression was upregulated and mutational analyses demonstrated a high rate (79 %) of FLT3
mutations. Hypomethylating agents induced reversal of GATA3 silencing, and gene expression profiling revealed
downregulation of hematopoietic stem cell genes and upregulation of T cell differentiation.
Conclusions: We propose GATA3low ETP-ALL as a novel stem cell-like leukemia with implications for the use of
myeloid-derived therapies.
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Background
GATA3 is a transcription factor with a pivotal role in
multiple developmental steps of T lymphopoiesis [1, 2],
including the development of early T cell precursors
(ETPs), a rare subpopulation of cells sharing characteris-
tics with multipotent hematopoietic progenitors in the
bone marrow [3]. ETPs are considered the most immature
thymic cells with potential for complete T cell differen-
tiation and retain plasticity for differentiation towards
dendritic, NK, B, or myeloid cells [4]. In a murine
model, GATA3 was required for the development of
ETPs, whereas totipotent hematopoietic stem cells
(HSCs) remained unaffected by in vivo manipulation of
GATA3 expression levels. Indeed, in murine HSCs,
GATA3 was silenced by DNMT3A-dependent DNA
hypermethylation [5]. By losing repressive epigenetic
marks during T lymphopoiesis, GATA3 functions as a
key regulator of T cell differentiation through the inter-
action with a multitude of target genes that differ in a
subpopulation specific manner [6]. For example, GATA3
was reported to restrain Notch activity, repress NK-cell
fate and upregulate T cell lineage genes to facilitate T cell
differentiation [7].
Lack of GATA3 has been linked to cancerogenesis, as
absence of GATA3 expression was associated with poor
prognosis and undifferentiated tumors in breast cancer
[8]. Moreover, several other cancers exhibited aberrant
GATA3 expression, including urothelial carcinoma [9],
renal cell carcinoma [10], pancreatic cancer [11], cervical
cancer [12], or Hodgkinʼs lymphoma [13]. In childhood
B cell precursor acute lymphoblastic leukemia (BCP-ALL),
specific germline variants of GATA3 were associated with
a higher incidence of BCP-ALL and a higher risk of re-
lapse [14, 15].
Given GATA3’s prominent role in both cancerogenesis
and T cell development, we investigated GATA3 in ETP-
ALL. ETP-ALL is a subtype of T-ALL characterized by a
distinct gene expression profile (GEP) and a distinct
immunophenotype with lack of CD1a and CD8, weak
expression of CD5 and additional expression of more
than 1 myeloid and/or stem cell marker [16]. ETP-ALL
accounts for 11–15 % of cases with T-ALL [16–18] with
similar distributions among pediatric and adult cohorts.
We and others have characterized the mutational land-
scape of ETP-ALL with alterations in genes involved in
cytokine and RAS signaling (e.g., NRAS, KRAS, FLT3,
and JAK1), epigenetic regulation (e.g., EZH2, DNMT3A,
and SUZ12), and hematopoietic development (e.g., ETV6,
RUNX1, and IKZF1) [19, 20]. Notably, the incidence of acti-
vating NOTCH1 mutations is considerably lower in ETP-
ALL (15 %) when compared to T-ALL (higher than 50 %)
[17, 21]. GATA3 inactivating mutations were reported in
9 % of pediatric ETP-ALL patients predominantly affecting
the DNA binding domain [19].
The prognostic relevance of ETP-ALL is controversially
discussed. Comparing ETP-ALL with non-ETP-ALL,
some reports indicate adverse prognosis in pediatric and
adult patients with ETP-ALL with CR rates of 58–73 %,
median event-free survival of 1.2 years, and 3-year overall
survival of 30–60 % [16, 17, 22]. Other groups found
similar outcome of ETP-ALL and non-ETP-ALL patients
with 5-year overall survival rates of 67–93 and 77–92 %,
respectively [23, 24].
Given the critical role that GATA3 plays in early
lymphoid development, we investigated GATA3 in ETP-
ALL, a stem cell-like leukemia blocked at the crossroads
of lymphoid and myeloid differentiation. We hypothe-
sized that aberrant GATA3 expression would divert
ETP-ALL from the lymphoid fate and determine a novel
biological subgroup of ETP-ALL.
Methods
Patient samples
Additional file 1: Figure S1 provides an overview over
the sample cohorts and subsequent experiments.
Gene expression data (Affymetrix HG-U133 Plus 2.0
or A + B) were available for adult T-ALL (n = 83; including
30 patients with ETP-ALL and 53 patients with non-ETP-
ALL, defined by gene expression profiling [16], GEO ac-
cession number GSE78132), BCP-ALL (n = 81, GSE13204)
[25], normal controls (NC; n = 24, GSE13204) [25], and
acute myeloid leukemia (AML; n = 130) [26, 27]. The
T-ALL subgroup included consecutive patients with newly
diagnosed ALL studied between 1999 and 2005 at two ref-
erence laboratories [25, 28].
Based on immunophenotyping of diagnostic samples
at the central diagnostic reference laboratory of the Ger-
man Multicenter Study Group for Acute Lymphoblastic
Leukemia (GMALL) in Berlin, Germany, we identified
additional 70 ETP-ALL samples [17]. Sufficient RNA for
GATA3 mRNA expression analysis was available for all
70 samples, and sufficient genomic DNA (gDNA) for
methylation assays was available for 69 samples of these
adult ETP-ALL cases. As reference cohort, we used 112
non-ETP-ALL patients, of which 21 (19 %) had an
immunophenotype of early T-ALL, 20 (18 %) of mature
T-ALL, and 71 (63 %) of thymic T-ALL.
All patients, including the two independent cohorts
of T-ALL, and normal controls gave written informed
consent to participate in the study according to the
Declaration of Helsinki. The studies were approved by
the ethics board of the Johann Wolfgang von Goethe
University, Frankfurt/Main, Germany.
Nucleic acid preparation and molecular characterization
Pretreatment bone marrow and peripheral blood sam-
ples from patients were used for gDNA and total RNA
extraction using TRIzol (Life Technologies, Grand Island,
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NY, USA) according to the manufacturer’s protocol with
minor modifications. Complementary DNA (cDNA) was
synthesized using 500 ng of total RNA and avian myelo-
blastosis virus reverse transcriptase (RT-AMV; Roche,
Mannheim, Germany) in the presence of RNase inhibitor
(RNasin; Roche, Mannheim, Germany).
Samples of patients with ETP-ALL (n = 70) and non-
ETP-ALL (n = 112) were investigated by comparative
multiplex real-time PCR (RT-PCR) for expression of
GATA3 (FWD: 5′-ACTACGGAAACTCGGTCAG-3′,
REV: 5′-GTAGGGATCCATGAAGCAG-3′, Probe: 5′-CG
GTGCAGAGGTACCCTCCG-3′) and glucose-6-phosphate
isomerase (GPI) as a housekeeping gene. Relative GATA3
expression values of ETP-ALL (n = 70) and non-ETP-ALL
(n = 112) were normalized to GATA3 expression in the hu-
man T-ALL cell line Jurkat. We identified a bimodal distri-
bution of GATA3 mRNA expression levels by K-means
clustering and defined a cutoff at an expression level of 0.2
relative to Jurkat and defined all samples with GATA3 ex-
pression below that cutoff as GATA3low and samples with
higher expression as GATA3high (Fig. 1).
Western blot
GATA3 protein levels were measured using standard
western blotting techniques using the GATA3 antibody
HG3-35 (Santa Cruz Biotechnology Inc., Dallas, TX, USA).
Gene expression profiling
A GATA3-associated GEP was generated from data of
83 adult T-ALL patients (including 30 ETP-ALL and 53
non-ETP-ALL samples defined by hierarchical clustering
using a list of genes reported as differentially expressed
in pediatric ETP-ALL [16], GEO accession number
GSE78132). For analysis, common probe sets between
HG-U133 Plus 2.0 and HG-U133 A + B (Affymetrix,
Santa Clara, CA, USA) were identified and quantile nor-
malized. For ANOVA analysis, the type of chip was inte-
grated as a random effect to take the batch effect into
account. GATA3 expression was calculated from signals
obtained from probe sets 209602_s_at, 209603_at, and
209604_s_at, respectively. As for the RT-PCR expression
levels, we identified a bimodal distribution of GATA3-
normalized expression values and defined a cutoff at 8.2
on a logarithmic scale to categorize patients below that
cutoff as GATA3low and with higher expression as
GATA3high. A GATA3-dependent GEP was generated by
the comparison of the expression profiles from GATA3low
(n = 11) and GATA3high (n = 72) samples. Lists of genes
with at least 1.5-fold under- or overexpression comparing
GATA3low and GATA3high were generated (Additional file
2: Table S1), and statistical significance was calculated by
ANOVA with a FDR ≤0.05. Data analysis was carried out
with Partek Genomic Suite v6.6 Software (Partek Inc., St.
Louis, MO, USA).
Lists of up- and downregulated genes (Additional file
2: Table S1) were uploaded to the DAVID Bioinformatics
server (http://david.abcc.ncifcrf.gov) to define enriched
KEGG pathway annotations [29].
Additionally, GEP was performed on the Affymetrix®
HG-U133 Plus 2.0 platform with ETP-ALL cell lines
(PER-117, Loucy, in triplicates) and non-ETP-ALL cell
lines (BE13, Molt4, Jurkat, RPMI8402; in duplicates)
(GEO accession number GSE78166).
For gene set enrichment analysis (GSEA), GATA3-su-
pervised GEPs were examined for enrichment of curated
gene sets representing ETP-ALL [19], HSC [30], T cell
differentiation [30], granulocyte/macrophage progenitors
(GMP) [30], and myeloid/lymphoid progenitors (MLP) [31]
Fig. 1 GATA3 mRNA expression in patient samples. a Affymetrix-based mean differential expression of GATA3 based on normalized expression
values in normal controls (NC) and selected hematological disorders. Horizontal lines indicate mean GATA3 expression s.e. Note the segmented
y-axis. b RT-PCR-based analyses of GATA3 mRNA expression relative to Jurkat on a logarithmic scale revealed lower GATA3 expression in ETP-ALL
(n = 70) than in non-ETP-ALL (n = 112) (4.82 vs. 6.29, p = 0.0005 indicated by asterisk). We identified a bimodal distribution of GATA3 expression by
K-means clustering with a cutoff at a relative expression of 0.2 (indicated by the dotted line). The GATA3low cohort contained only cases with ETP-ALL
(i.e., GATA3low ETP-ALL)
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comparing GATA3low ETP-ALL (n = 11) and GATA3high
ETP-ALL (n = 19) cases. Additionally, we used decitabine-
induced changes of GEP as a discriminator to analyze
enrichment of these curated gene lists in PER-117 cells.
Data analyses were carried out with the GSEA desktop
application version 2.0.12 [32, 33] from the Broad Institute
(http://www.broadinstitute.org/gsea).
Methylation analysis
We assessed global DNA methylation analyses in 12
ETP-ALL and 14 BCP-ALL samples by the Illumina
Infinium® HumanMethylation450 BeadChip platform.
Hybridization was performed according to the manufac-
turer’s protocol. The signals generated for unmethylated
and methylated cytosine nucleotides by single-nucleotide
extension of locus-specific methylation probes were trans-
formed into β values ranging from 0 to 1 (representing 0
to 100 %) for each of the 450,000 interrogated CpG resi-
dues. We assumed differential methylation, if more than
three differentially methylated sites (DMS) with a p value
<0.05 were present for each gene and the absolute differ-
ence of the corresponding β values ð△βÞ was greater than
0.17. Data analysis was carried out with Partek Genomic
Suite v6.6 Software (Partek Inc., St. Louis, MO, USA).
Sufficient amounts of gDNA for bisulfite conversion
was available for 69 ETP-ALL and 48 AML samples,
which was carried out using the EpiTect Bisulfite Kit
(QIAGEN, Hilden, Germany) according to the manufac-
turer’s instructions. For validation of the differentially
methylated region of GATA3 detected by global methyla-
tion analysis, primers were designed for amplification
and pyrosequencing based on the bisulfite converted
sequence of GATA3 (genomic location: GRCh37:
chr10:8097750-8098004) and used in the Pyrosequencing
Assay Design Software v1.0 (Biotage, Uppsala, Sweden) for
assay design. Amplification of a 255-bp sequence was car-
ried out in all 69 bisulfite converted ETP-ALL samples
using a 5′-GGAGGAGGTGGATGTGTTTTTTAAT-3′
forward and a 3′-AACCCCAATTTTTTTATAAATAAAC
CA-5′reverse biotinylated primer. Additionally, 13 rep-
resentative samples of the non-ETP-ALL cohort were
selected for analysis by pyrosequencing; 100 ng of
bisulfite-converted gDNA was used per reaction with
Taq-DNA-polymerase (Hot Start Mix S, peqlab, Erlangen,
Germany). Samples were analyzed for specificity and cor-
rect size by 2 % agarose gel electrophoresis.
For pyrosequencing, a 5′-GTTACGGTGTAGAGGTA
TTTT-3′ sequencing primer was used. The percentage
of CpG site methylation was calculated through the ratio
of the relative content of thymine (i.e., unmethylated
cytosine) and the relative content of cytosine (i.e., meth-
ylated cytosine) using the Pyro Q-CpG Software version
1.0.9 (Biotage, Uppsala, Sweden). Four of 12 CpG sites
covered by the sequencing primer failed quality control
due to the reference sequence pattern at the end of the
amplicon. The remaining eight CpG sites were included
to calculate the mean percentage of methylation for each
sample.
Cell culture and chemicals
The immature T-ALL cell line PER-117 [34] was grown
in RPMI media with 10–20 % fetal bovine serum and
cultured at 37 °C in a 5 % CO2 humidified chamber.
PER-117 exhibited an immature phenotype resembling
ETP-ALL (CD7+CD5−CD1a−cyCD3+CD33+TdT−CD10
−CD34−CD117−), and gene expression profiling based
on microarray analysis revealed an ETP-ALL phenotype
(Additional file 3: Figure S2) including high expression
of GATA2, CEBPα, or NFE2 and low expression of
LEF1 and GATA3 (GATA3low ETP-ALL).
Additionally, the ETP-ALL cell line Loucy (with high
GATA3 expression, GATA3high ETP-ALL) and the non-
ETP-ALL cell lines, Jurkat, Molt4, BE13, and RPMI8402
were obtained from the German Resource Center for
Biological Material, DSMZ (Braunschweig, Germany)
and previously characterized on a molecular level [35].
5-Azacytidine and 5-aza-deoxycytidine were purchased
from Sigma-Aldrich (St. Louis, MO, USA).
Cell proliferation assay
Cell proliferation was measured with the WST-1 reagent
according to the manufacturer’s instructions (Roche Diag-
nostics GmbH, Germany). Cell lines were treated with
various concentrations of 5-azacytidine (Sigma-Aldrich,
St. Louis, USA) and 5-aza-deoxycytidine (Sigma-Aldrich,
St. Louis, USA), and absorbance was measured after 48,
72, and 96 h by optical density absorption analyses at a
wavelength of 450 nm using an ELISA multiplate reader.
Apoptosis assay
Apoptosis was measured using Annexin V Apoptosis De-
tection Kit (BD Pharmingen, Heidelberg, Germany). Cells
were labeled with Annexin V and 7-amino-actinomycin D
(7-AAD) after treatment with 5-azacytidine and 5-aza-
deoxycytidine. Analyses were performed by FACS Calibur
(Becton-Dickinson) to determine the percentage of apop-
totic cells from combined 7-AAD incorporation and
Annexin V binding.
Statistical analysis
The statistical difference of gene expression between two
independent groups was tested by the non-parametric
Mann-Whitney U test. For non-parametric correlation
of mRNA expression and DNA methylation, Spearman’s
rank correlation coefficient was calculated. Fisher’s exact
test was used to test for the association between two
kinds of classifications (e.g., 2 × 2 contingency table).
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For all tests, a p value <0.05 (two-sided) was consid-
ered to indicate a significant difference. All calculations
were performed using the SPSS software version 19
(SPSS Inc., Chicago, IL, USA), GraphPad Prism® software
version 5 (GraphPad Software Inc., La Jolla, CA, USA),
and Partek Genomic Suite v6.6 Software (Partek Inc., St.
Louis, MO, USA).
Results
Lack of GATA3 expression in ETP-ALL
We first assessed GATA3 mRNA expression by micro-
array analysis and found that mean expression of GATA3
was higher in T-ALL (4.88 ± 0.41, mean ± s.e., n = 83) than
in other cohorts (NC 1.33 ± 0.11, n = 24; AML 0.57 ± 0.05,
n = 130; and BCP-ALL 3.28 ± 0.66, n = 81; all values are
mean ± s.e., p < 0.001) (Fig. 1a).
To further explore GATA3 expression in T-ALL, we
analyzed GATA3 mRNA expression by quantitative
RT-PCR in larger cohorts of ETP-ALL (n = 70) and
non-ETP-ALL (n = 112). The mean relative expression of
GATA3 was lower in ETP-ALL than in non-ETP-ALL
(4.82 ± 0.78 vs. 6.29 ± 0.60, mean ± s.e., p = 0.0005). Inter-
estingly, we found a bimodal distribution of GATA3 ex-
pression with one third of ETP-ALL patients lacking
GATA3 expression (23/70, 33 %, GATA3low ETP-ALL). In
contrast, none of 112 non-ETP-ALL samples lacked
GATA3 expression, which consisted of 71 thymic, 21 early,
and 20 mature T-ALL patient samples (Fig. 1b). In agree-
ment with this, the non-ETP-ALL cell lines Molt4, Jurkat,
RPMI8402, and BE13 all expressed GATA3, while PER-
117 [34], a cell line with an ETP-ALL immunophenotype
and GEP (Additional file 3: Figure S2) lacked GATA3
expression. Western blotting revealed that differential
GATA3 mRNA expression translated into differential
protein expression levels (Additional file 4: Figure S3).
GATA3 silencing is mediated by aberrant DNA
methylation
To explore the regulation of GATA3 expression, we in-
vestigated global DNA methylation on the Illumina
HumanMethylation 450 k platform in 12 ETP-ALL sam-
ples (Fig. 2), which were selected according to GATA3
mRNA expression (GATA3low vs. GATA3high) and muta-
tional status of DNMT3A. The genomic locus of GATA3
(NC_000010.10) was represented by 72 CpG sites.
Four of 12 ETP-ALL patients were defined as GATA3low
(mean GATA3 expression ± s.e.: 0.08 ± 0.05), while the
remaining eight patients were GATA3high (mean GATA3
expression ± s.e.: 6.4 ± 1.5). GATA3 DNA methylation of all
72 GATA3 CpG sites was higher in GATA3low ETP-ALL
compared to GATA3high ETP-ALL (mean 45 vs. 23 %,
p < 0.0001). We detected 35 of 72 GATA3 CpG sites with
a significantly higher degree of methylation in GATA3low
ETP-ALL compared to GATA3high ETP-ALL (mean 46 vs.
19 %, p < 0.0001). All 35 DMS clustered in a 6-kb region
(genomic location: GRCh37: chr10:8095478-8101513; in-
dicated by the grey box in Fig. 2a), which mapped to a
GATA3 CpG island (GRCh37: chr10:8091375-8098329)
that was previously reported to be differentially methyl-
ated in cancer [10, 36].
Comparing DNMT3A-mutated (n = 6) and DNMT3A
wild-type (n = 6) ETP-ALL, we found lower GATA3
methylation in DNMT3A-mutated versus DNMT3A
wild-type samples (16 vs. 35 %, p < 0.0001) at the GATA3
CpG island (GRCh37: chr10:8091375-8098329), but GATA3
expression, as determined by RT-PCR, was not different be-
tween the DNMT3A mutated (n = 6) and wild-type (n = 6)
ETP-ALL cases (4.4 vs. 3.8, p = 0.84). Notably, all 16 DMS
within the GATA3 CpG island clustered in a 3.3-kb region
(GRCh37: chr10:8092037-8095363) just upstream of the
6-kb region that correlated to GATA3 gene mRNA ex-
pression, but remarkably without overlap.
To validate these findings in a larger sample set, DNA
methylation was analyzed by pyrosequencing in 69
ETP-ALL samples; 11 of 69 samples were also investi-
gated by the Illumina Human Methylation assay. Cap-
turing a segment of the GATA3 CpG island (GRCh37:
chr10:8097750-8098004) (Additional file 5: Figure S4),
we assessed 64 samples of which both GATA3 mRNA
expression and GATA3 DNA methylation were available.
We confirmed a high degree of concordance between py-
rosequencing and the Illumina Human Methylation assay
in samples analyzed in parallel on both platforms (n = 11,
R2 = .94). By pyrosequencing, we confirmed a higher de-
gree of DNA methylation in GATA3low ETP-ALL (n = 19)
compared to GATA3high ETP-ALL (n = 45) (mean 46 vs.
21 %, p < 0.0001). GATA3 expression and DNA methy-
lation were inversely correlated (r = −0.73, p < 0.0001)
(Fig. 2b). When we compared ETP-ALL to non-ETP-
ALL, DNA methylation was lower in non-ETP-ALL
(5 %, range 3–8 %, n = 13) than in ETP-ALL (28 %,
range 5–91 %, n = 69; p < 0.0001) (Fig. 2c).
GATA3low ETP-ALL is associated with FLT3 mutations
Our group previously assessed the mutational landscape
of ETP-ALL by whole exome sequencing [20] and tar-
geted NGS re-sequencing [37]. Within this cohort of
ETP-ALL, we have investigated the mutational pattern
with respect to GATA3 expression (Additional file 6:
Table S2). In contrast to pediatric cohorts, we found no
GATA3 mutations in this cohort, including a screen for
hotspot mutations of exon 4 in an additional expansion
cohort of 70 samples of adult ETP-ALL.
Comparing GATA3low and GATA3high ETP-ALL, we
found FLT3 mutations (including both internal tandem
duplications and mutations in the tyrosine kinase domain)
in 79 % of GATA3low ETP-ALL (15/19), while only 15 % of
GATA3high ETP-ALL (7/46) were FLT3 mutated (p < 0.001).
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Comparing FLT3+- and FLT3−-ETP-ALL, we found lower
GATA3 expression (0.5 vs. 7.0, p < 0.0001) and higher
GATA3 methylation as detected by pyrosequencing (51 vs.
8 %, p < 0.0001) in FLT3+-ETP-ALL. NOTCH1 mutations
were generally infrequent in our cohort of ETP-ALL (11/
65, 17 %) and less frequent still in GATA3low ETP-ALL
than in GATA3high ETP-ALL (2/19, 11 % vs. 9/46, 20 %).
Notably, we detected mutations in genes of the PRC2
complex in only a small number of adult ETP-ALL pa-
tients (5/70, 7 %) with marginal differences between
GATA3low and GATA3high ETP-ALL cases (2/23, 9 vs.
3/47, 6 %). DNMT3A, EZH2, SUZ12, and EP300 muta-
tions were similarly distributed among GATA3low and
GATA3high samples as well as all other investigated
genes.
Distinct transcriptional program of GATA3low ETP-ALL
To explore differences of the transcriptional program,
microarray expression data of 83 T-ALL patients were
available; 11 of 83 patients were defined as GATA3low,
while the remaining 72 patients were classified as
GATA3high. Including probe sets with at least 1.5-fold
overexpression, we detected 1435 differentially expressed
probes sets in GATA3low compared to GATA3high T-ALL
cases (Additional file 2: Table S1). Hierarchical clustering
with this gene list revealed a GATA3low-derived gene ex-
pression signature (Fig. 3a). Importantly, this GATA3low
GEP identified all but one case of ETP-ALL in an inde-
pendent cohort of pediatric T-ALL (Additional file 7:
Figure S5) [16]. Annotation of the top 267 DEG (i.e.,
genes with fold change ≥3×) using the KEGG pathway
Fig. 2 GATA3 silencing is regulated by DNA methylation in ETP-ALL. a 10p15 chromosome plot depicting DNA methylation of 12 ETP-ALL patient
samples as assessed by Illumina Infinium® HumanMethylation450 BeadChip. β values representing DNA methylation for each patient (upper panel)
and mean DNA methylation (lower panel) of GATA3low ETP-ALL (n= 4, blue) and GATA3high ETP-ALL (n = 8, red). Comparing GATA3low ETP-ALL (n= 4,
blue) with GATA3high ETP-ALL (n = 8, red), 35 differentially methylated sites were located within a 6-kb segment of GATA3 (indicated by the gray box),
including the CpGs that were analyzed by pyrosequencing in a larger cohort of patients. b GATA3 DNA methylation as assessed by pyrosequencing (of
CpGs within the gray box in a) was negatively correlated to GATA3 mRNA expression in ETP-ALL (n = 64, r = −0.73, p < 0.0001). The dotted line indicates
the cutoff to distinguish GATA3low (empty dots) and GATA3high (solid dots) samples. c Pyrosequencing revealed higher GATA3 DNA methylation in
ETP-ALL (n = 69) than in non-ETP-ALL (n = 13) (28 vs. 5 %, p < 0.0001 indicated by asterisk). Empty and solid dots indicate GATA3low and GATA3high
ETP-ALL, while triangles indicate non-ETP-ALL
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database demonstrated significant enrichment of up-
regulated genes associated to cancer and, notably,
AML, while genes associated to T cell signaling were
downregulated in GATA3low samples (Additional file 8:
Table S3).
Next, we intended to dissect molecular differences by
comparing GATA3low and GATA3high in cases with
ETP-ALL only. In a cohort of 30 adult patients with
ETP-ALL, we identified 11 patient samples as GATA3low
and 19 as GATA3high (Additional file 9: Figure S6).
Applying GSEA, we found significant enrichment of ETP-
ALL-associated genes (NES = 1.51, p = 0.01, FDR = 0.05)
(Fig. 3b) and depletion of genes involved in T cell differen-
tiation (NES = −1.6, p = 0.008, FDR = 0.01) in GATA3low
ETP-ALL cases (Fig. 3c). Moreover, we also found en-
richment for GMP-based genes (NES = 1.5, p = 0.06,
FDR = 0.1, Fig. 3d) and MLP-based genes (NES = 1.5,
p = 0.04, FDR = 0.14, Fig. 3e) in the GATA3low group.
Decitabine restores GATA3 expression in PER-117 cells
Given the high degree of GATA3 DNA methylation, we
studied whether hypomethylating agents (HMA) could
convert methylation-induced GATA3 silencing. We used
PER-117 as a model for GATA3low ETP-ALL with high
GATA3 DNA methylation (mean DNA methylation
92 % 1 %), low GATA3 mRNA expression (relative ex-
pression to Jurkat 0.002), and an ETP-like immunophe-
notype and GEP (Additional file 3: Figure S2). We
evaluated GATA3 DNA methylation by pyrosequencing
and GATA3 expression by RT-PCR after treatment with
decitabine.
Fig. 3 GATA3low ETP-ALL exhibits a distinct transcriptional program. a Heat map of 1.5-fold DEG comparing GATA3low (n = 11) with GATA3high
(n = 72) in patients with T-ALL (n = 83), including 30 patients with ETP-ALL and 53 patients with non-ETP-ALL. b–e GSEA restricted to ETP-ALL
(n = 30) comparing GATA3low (n = 11) and GATA3high ETP-ALL (n = 19) revealed enrichment of ETP-ALL genes (NES = 1.5, p < 0.01) (b), depletion of
T cell differentiation genes (NES = 1.6, p < 0.008) (c), enrichment of GMP-based genes (NES = 1.5, p = 0.06) (d), and enrichment of MLP-based genes
(NES = 1.5, p = 0.04) in GATA3low ETP-ALL (e)
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Treatment of PER-117 with decitabine (48 h, 5 μM)
increased GATA3 mRNA expression by 2.2-fold (n = 4,
p < 0.001) while lowering GATA3 DNA methylation from
91 to 78 % (n = 4, p < 0.05) (Fig. 4a). In contrast, another
ETP-ALL cell line, Loucy, exhibited higher GATA3 expres-
sion (GATA3high ETP-ALL) than PER-117 and treatment
with decitabine failed to induce GATA3 expression. In
PER-117, decitabine induced 50 % growth inhibition at a
concentration (IC50) of 4 μM (n = 9, p < 0.05) and en-
hanced apoptosis at the IC50 from 10 to 29 % after 48 h
(n = 5, p < 0.05) (Fig. 4b).
We analyzed global gene expression of PER-117 cells
by Affymetrix microarrays before and after treatment
with decitabine at a final concentration of 5 μM at three
time points (0, 24, and 48 h). At both 24 and 48 h after
decitabine treatment, we detected significant changes
in global gene expression compared to untreated cells
(Fig. 4c) with 2019 differentially expressed probe sets
(fold change of ≥1.5 and FDR <0.05) after 48 h of exposure
to decitabine (Fig. 4d). Principal component analysis re-
vealed differential changes of global gene expression after
24 and 48 h: GEP changes represented by the first prin-
cipal component expanded up until 48 h, while GEP
changes subsumed by the second and third principal
components were nearly completely reversible after
48 h (Fig. 4c).
Pathway analysis of all DEG after 48 h of decitabine
treatment identified significant upregulation of p53
Fig. 4 Decitabine reverses GATA3 silencing in PER-117 cells, an in vitro model for GATA3low ETP-ALL. a Treatment with decitabine (5 μM) increased
GATA3 mRNA expression (n = 4, p < 0.001 indicated by the asterisk, all values are mean ± s.d.) and decreased GATA3 DNA methylation after 48 h
(n = 4, p < 0.05 indicated by the asterisk, all values are mean ± s.d.) as detected by pyrosequencing. Note the two segments of the right y-axis for
improved visualization. b Treatment with decitabine impaired proliferation as detected by WST assay with an IC50 of 4 μM and induced apoptosis
as detected by flow cytometry of incorporation of 7-AAD and Annexin V binding after 48 h (n ≥ 5, p < 0.05 indicated by the asterisk, all values are
mean ± s.d). c Principal component analysis of global gene expression profiles of PER-117 cells before and after treatment with decitabine (5 μM).
d Venn diagram indicating the number of differentially expressed probe sets in PER-117 cells after 24 and 48 h and at both time points compared
with no treatment
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signaling genes (e.g., FAS, CDKN1a, or MDM2), while
genes involved in cell cycling (e.g., CDK6, RB1, GSK3B, or
E2f5) were downregulated upon treatment with decitabine.
Moreover, we found downregulation of cancer-associated
genes such as BCL2, FLT3LG, or PIK3r5 in cells treated
with decitabine (Additional file 10: Table S4). Importantly,
GATA3 ranked among the top upregulated genes (fold
change of 2.2, p < 0.0001) confirming doubled GATA3
mRNA expression levels determined by RT-PCR.
To further characterize the transcriptional changes
upon decitabine treatment, we performed GSEA compar-
ing untreated with treated PER-117 cells. In cells treated
with decitabine, we found downregulation of HSC genes
(NES = 1.28, p < 0.001, FDR = 0.16) and, in line with in-
creased GATA3 expression, upregulation of T cell dif-
ferentiation (NES = 1.16, p = 0.06, FDR = 0.22).
Discussion
Here, we discovered a novel, molecularly distinct subgroup
of T-ALL patients lacking GATA3 expression (GATA3low).
All GATA3low T-ALL patients exhibited an immuno-
phenotype of ETP-ALL, while GATA3high T-ALL pa-
tients were of thymic, early, or mature subtypes. The
subgroup of GATA3low ETP-ALL is molecularly and
clinically relevant as it lacks T lineage commitment in
favor of a sustained myeloid gene expression signaling
and a high rate of FLT3 mutations.
Clustering analysis revealed a third of our cohort’s
ETP-ALL samples to be GATA3low. To study mechanisms
of silenced GATA3 mRNA expression, we investigated
DNA methylation. We identified a CpG island of GATA3
with consistently higher GATA3 DNA methylation in
GATA3low ETP-ALL compared to GATA3high ETP-ALL
including more than 30 DMS. This GATA3 CpG island
was differentially methylated in renal cell carcinoma [10]
and thyroid adenocarcinoma. In fact, cg01255894, a hyper-
methylated CpG site in ETP-ALL, was among the top 25
methylation probes that were most negatively correlated
with gene expression [36]. Notably, GATA3 DNA hyper-
methylation was absent in non-ETP-ALL indicating that
GATA3 silencing was a distinct mechanism in ETP-ALL.
It is tempting to relate this finding to reports of murine
DNMT3A-deficient mice, where GATA3 silencing was as-
sociated with DNMT3A-dependent DNA hypermethyla-
tion in HSC [5]. Indeed, when we compared DNMT3A
mutated and DNMT3A wild-type ETP-ALL, we found
lower GATA3 DNA methylation in samples with mutated
DNMT3A, but GATA3 mRNA expression was not differ-
ent between DNMT3A wild-type and mutated ETP-ALL.
Thus, DNMT3A contributes to GATA3 DNA methylation;
however, redundant mechanisms are likely required for
GATA3 silencing in GATA3low ETP-ALL. Importantly,
hypermethylation of GATA3 was found only in the subset
of GATA3low ETP-ALL, but not in other leukemic subtypes
such as typical T-ALL or BCP-ALL. Notably, in 49 samples
from patients with AML, GATA3 expression was similarly
low as in GATA3low ETP-ALL (mean 0.2 vs. 0.03), but
DNA hypermethylation was absent in AML (17 vs. 46 %).
Thus, GATA3low ETP-ALL may reflect the transformed
precursor stage of yet non-committed ETP that physiolo-
gically harbor GATA3 DNA hypermethylation.
In order to explore the cell of origin of GATA3low
ETP-ALL, we identified a GATA3low-specific GEP in a
cohort of T-ALL, including ETP-ALL and non-ETP-ALL
patient samples. GATA3low and GATA3high samples gen-
erated distinct gene expression clusters in a supervised
analysis. The biological significance of this observation
was underscored when we validated our GATA3low signa-
ture by identifying cases with ETP-ALL in an independent
cohort of pediatric patients with T-ALL [16] by unsuper-
vised hierarchical clustering. Moreover, pathway annotation
of DEG indicated upregulation of myeloid genes and down-
regulation of T cell differentiation. Perhaps unsurprisingly,
we found depletion of T cell signaling and enrichment of
myeloid signaling when we performed GSEA comparing
GATA3low ETP-ALL with T-ALL. By restricting the analysis
to ETP-ALL only, we confirmed enrichment of GMP and
MLP signatures and depletion of T cell differentiation in
GATA3low samples compared to GATA3high ETP-ALL,
which pointed at a specific molecular bracket within ETP-
ALL. The specificity of GATA3 in this regard was further
underscored when we analyzed other relevant transcription
factors involved in T cell differentiation. Other transcription
factors, such as MEF2C, PU.1, BCL11B, LMO1-3, HOXA1,
TCF-1, or LYL1 failed to identify subsets with meaningful
gene set enrichment in neither “typical” T-ALL nor ETP-
ALL. Only the transcription factor LEF1 segregated cases
into subgroups with similar gene set enrichment patterns
as GATA3 subgroups, albeit with significant overlap of
GATA3low/LEF1low cases. LEF1 is an important effector of
WNT signaling and, like GATA3, known to be essential for
early stages of T cell development. In T cell malignancy,
LEF1 was implicated in transforming T cells in the absence
of TCF1 [38].
The observation of a myeloid gene expression signa-
ture was further supported by the high frequency of
FLT3 mutations in GATA3low ETP-ALL. It is important
to note that neither of the investigated cases fulfilled the
diagnostic criteria for leukemia of ambiguous lineage or
acute myeloid leukemia. Therefore, these findings point
to T-lymphoblastic precursors with multilineage potential
as cells of origin of GATA3low ETP-ALL. Indeed, enrich-
ment of ETP-ALL genes in GATA3low compared with
GATA3high ETP-ALL reinforced this assumption as ETP-
ALL by itself is characterized by upregulation of stem cell
genes and myeloid-derived gene expression [19].
Ultimately, the significance of GATA3low ETP-ALL as
a subgroup of ETP-ALL will depend on the implementation
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of distinct therapeutic interventions. In our ETP-ALL co-
hort, we found no significant outcome differences compar-
ing GATA3low and GATA3high ETP-ALL (1-year OS 75 vs.
79 %) in a retrospective analysis of 52 patients. In general,
the clinical outcome of ETP-ALL remains controversial, as
reports of adverse risk in pediatric and adult ETP-ALL
[16, 22, 39] have been challenged by reports indicating
no outcome differences between ETP-ALL and non-
ETP-ALL patient cohorts [23, 24]. This controversy
might be in part due to the definition of ETP-ALL by
GEP or flow cytometry as well as differences in treatment
intensities, especially MRD-directed approaches to treat-
ment intensification [16, 19, 23, 24, 40].
In any case, the mutational and transcriptional profile
of GATA3low ETP-ALL provides rationale for imple-
menting targeted therapies in patients with failure of
lymphoid-directed therapies. Low incidence of NOTCH1
mutations in GATA3low ETP-ALL will likely render
NOTCH-targeted therapies (e.g., γ-secretase inhibitors)
ineffective. On the other hand, FLT3 mutations were de-
tected in more than 75 % of GATA3low ETP-ALL and
our group has previously shown in vitro efficacy of FLT3
inhibitors in human T-ALL cell lines [17]. Importantly,
GATA3 DNA hypermethylation implicates epigenetic
therapies in GATA3low ETP-ALL, such as decitabine, a
hypomethylating agent approved for the treatment of
myelodysplastic syndrome, chronic myelomonocytic
leukemia, and AML. Our data demonstrate that decita-
bine induced apoptosis in PER-117 cells while lowering
GATA3 DNA methylation. Subsequent induction of
GATA3 expression may function as a surrogate of T
cell differentiation which we also observed in PER-117
cells upon decitabine treatment. This is in line with
murine breast cancer, where lack of GATA3 is associated
with undifferentiated tumors [8]. The IC50 of decitabine in
our experiments was comparable to AML cell lines
[41, 42], and current dosing of decitabine in AML re-
sults in a similar range of steady state plasma levels
[41]. Although further experiments are necessary to
evaluate in vivo efficacy of HMA in T-ALL, it is likely
that similar doses of decitabine will be required in T-ALL
and AML. It is important to note that forced GATA3 over-
expression alone failed to induce relevant changes in pro-
liferation, apoptosis, or differentiation in PER-117 cells,
which we attributed to GATA3 dose sensitivity. Instead,
subtle changes of GATA3 expression are needed to divert
aberrant DNA hypermethylation towards an equilibrium
of optimum methylation in T lymphoblasts [43], for which
GATA3 induction upon treatment with decitabine serves
as yet another example.
Conclusions
GATA3 silencing occurs in about one third of adult
ETP-ALL patients and is associated with GATA3 DNA
hypermethylation. Lack of GATA3 engages a transcrip-
tional program that is characterized by enrichment of
myeloid signatures and loss of T cell differentiation
against a background of both T-ALL and ETP-ALL.
We propose a novel stem cell-like leukemia termed
GATA3low ETP-ALL with a high frequency of FLT3
mutations as a distinct molecular entity with sensitivity to
hypomethylating agents.
Additional files
Additional file 1: Figure S1. Flowchart depicting the patient sample
cohorts. Strategy to define ETP-ALL is provided as well as platforms for
subsequent analyses. (JPG 93 kb)
Additional file 2: Table S1. List of DEG comparing patients with low
and high GATA3 mRNA expression. Microarray analyses of diagnostic
bone marrow samples of 83 adult patients with T-ALL were used to
generate a list of DEG comparing GATA3low and GATA3high. Only probe
sets with at least 1.5-fold up- or downregulation with respect to GATA3
expression and a FDR <0.05 were included. (XLSX 102 kb)
Additional file 3: Figure S2. PER-117 and Loucy are ETP-ALL cell lines.
Hierarchical clustering of ETP-ALL and non-ETP-ALL cell lines, using a set
of genes differentially expressed in pediatric patients with ETP-ALL
compared with non-ETP-ALL [20]. (PNG 63 kb)
Additional file 4: Figure S3. GATA3 expression in human leukemia cell
lines. (A) RT-PCR-based analysis of GATA3 mRNA expression relative to
Jurkat indicates differential GATA3 mRNA expression. (B) Western blot analysis
revealed differential GATA3 protein expression (predicted molecular weight
of 47 kDa). (JPG 35 kb)
Additional file 5: Figure S4. Pyrograms showing GATA3 DNA
methylation in ETP-ALL in eight consecutive CpG sites across 64 bases.
The sequence of the GATA3 amplicon is indicated at the top, while the
sequence at the bottom of each panel indicates the dispensation order.
The grey boxes highlight peaks resulting from sequential dispensations of
C and T from which DNA methylation was calculated (blue boxes). (A)
Representative ETP-ALL sample exhibiting high GATA3 DNA methylation.
(B) Representative ETP-ALL sample exhibiting low GATA3 DNA methylation.
(PNG 226 kb)
Additional file 6: Table S2. Next generation sequencing comparing
the mutational pattern of GATA3low (n = 5) and GATA3high ETP-ALL
(n = 13). Sanger Sequencing was performed for selected genes in an
extended cohort (n = 70) confirming a high rate of FLT3 mutations in
GATA3low ETP-ALL. (PNG 47 kb)
Additional file 7: Figure S5. The GATA3low gene expression profile
identified cases with ETP-ALL in an independent cohort of T-ALL.
Unsupervised hierarchical cluster analysis of diagnostic bone marrow
samples from 55 pediatric patients with T-ALL, using a set of genes
defined by low GATA3 expression in adult T-ALL. Classification of ETP-ALL
and non-ETP-ALL was performed according to the ETP gene expression
signature published along with this dataset. (PNG 484 kb)
Additional file 8: Table S3. KEGG pathway annotation of DEG in
GATA3low versus GATA3high T-ALL patients. Lists of threefold over- and
underexpressed genes of GATA3low patients were uploaded to DAVID
Bioinformatics Resources v6.7. Listed are selected KEGG annotated pathway
elements significantly enriched in GATA3low up- or downregulated DEGs.
(PNG 34 kb)
Additional file 9: Figure S6. Validation of the GATA3low ETP-ALL cluster
in adult patients with T-ALL using the ETP signature derived from
pediatric T-ALL. Unsupervised hierarchical cluster analysis of diagnostic
bone marrow samples from 83 adult patients with T-ALL, using a set of
genes defined in pediatric T-ALL [20]. Blue = GATA3low ETP-ALL (n = 11),
red = GATA3high (n = 72). Patients assigned to ETP-ALL and “typical” T-ALL
are indicated. (PNG 748 kb)
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Additional file 10: Table S4. KEGG pathway annotation of DEG in
PER-117 cells before versus after treatment with decitabine. Lists of 1.5-fold
over- and underexpressed genes of cells treated with decitabine (5 μM)
were uploaded to DAVID Bioinformatics Resources v6.7. Listed are selected
KEGG annotated pathway elements significantly enriched in cells treated
with decitabine. (PNG 61 kb)
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